BR112019011844A2 - Uso de pelo menos uma defensina - Google Patents
Uso de pelo menos uma defensinaInfo
- Publication number
- BR112019011844A2 BR112019011844A2 BR112019011844A BR112019011844A BR112019011844A2 BR 112019011844 A2 BR112019011844 A2 BR 112019011844A2 BR 112019011844 A BR112019011844 A BR 112019011844A BR 112019011844 A BR112019011844 A BR 112019011844A BR 112019011844 A2 BR112019011844 A2 BR 112019011844A2
- Authority
- BR
- Brazil
- Prior art keywords
- asthma
- reducing
- defensin
- persistent
- mild
- Prior art date
Links
- 102000000541 Defensins Human genes 0.000 title abstract 2
- 108010002069 Defensins Proteins 0.000 title abstract 2
- 208000006673 asthma Diseases 0.000 abstract 8
- 230000002085 persistent effect Effects 0.000 abstract 3
- 206010035664 Pneumonia Diseases 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 abstract 1
- 230000010085 airway hyperresponsiveness Effects 0.000 abstract 1
- 102000012265 beta-defensin Human genes 0.000 abstract 1
- 108050002883 beta-defensin Proteins 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 210000004969 inflammatory cell Anatomy 0.000 abstract 1
- 208000024710 intermittent asthma Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000306 sarcoidosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670991 | 2016-12-13 | ||
| PCT/EP2017/082535 WO2018108971A2 (en) | 2016-12-13 | 2017-12-13 | Methods for treating inflammatory conditions of the lungs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019011844A2 true BR112019011844A2 (pt) | 2022-05-10 |
Family
ID=61024712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019011844A BR112019011844A2 (pt) | 2016-12-13 | 2017-12-13 | Uso de pelo menos uma defensina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11413328B2 (https=) |
| EP (1) | EP3554532B1 (https=) |
| JP (2) | JP2020512287A (https=) |
| KR (1) | KR20190108106A (https=) |
| CN (1) | CN110290799A (https=) |
| AU (1) | AU2017376400A1 (https=) |
| BR (1) | BR112019011844A2 (https=) |
| CA (1) | CA3045079A1 (https=) |
| ES (1) | ES2994381T3 (https=) |
| MX (1) | MX2019006848A (https=) |
| RU (1) | RU2019120956A (https=) |
| SG (1) | SG10202012106WA (https=) |
| WO (1) | WO2018108971A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020004863A (es) * | 2017-11-10 | 2020-10-14 | Defensin Therapeutics Aps | Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro. |
| CN108815199B (zh) * | 2018-08-03 | 2021-10-01 | 南华大学 | 鼠衣原体在制备抗溃疡性结肠炎药物中的应用 |
| US11331269B2 (en) * | 2018-09-06 | 2022-05-17 | Massachusetts Institute Of Technology | Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment |
| CN113164390A (zh) | 2018-10-09 | 2021-07-23 | 达特·特兰 | 用于增强阳离子大环肽的全身递送能力、耐受性和效力的组合物和方法 |
| JP7479381B2 (ja) * | 2019-01-07 | 2024-05-08 | アエスクルス バイオ エーピーエス | 治療または予防に使用するためのディフェンシン断片 |
| CA3132564A1 (en) * | 2019-03-14 | 2020-09-17 | Om Pharma Sa | Process for making stable bacterial extracts and their use as pharmaceuticals |
| US12472231B2 (en) | 2020-03-18 | 2025-11-18 | The University Of Hong Kong | Compositions of anti-viral peptides and methods of use thereof |
| CN113262297A (zh) * | 2020-11-02 | 2021-08-17 | 中南大学湘雅二医院 | 一种基于巴氏菌的治疗性肺癌疫苗及其配置方法和应用 |
| CN113521047B (zh) * | 2021-08-23 | 2022-10-04 | 新疆医科大学第四附属医院 | 丁酸盐在制备慢性阻塞性肺疾病药物中的应用 |
| CN118451094A (zh) * | 2021-12-27 | 2024-08-06 | 港大科桥有限公司 | 抗病毒肽及其使用方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| WO2003070176A2 (en) | 2002-02-19 | 2003-08-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Modified defensins and their use |
| CA2487895A1 (en) | 2002-05-31 | 2003-12-11 | Ciphergen Biosystems, Inc. | Defensins: use as antiviral agents |
| GB0521139D0 (en) * | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
| US7528107B2 (en) | 2005-11-30 | 2009-05-05 | Auburn University | Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins |
| WO2008115390A2 (en) | 2007-03-16 | 2008-09-25 | The Hamner Institutes For Health Sciences | Methods of using defensins to treat diabetes |
| AU2009209565B2 (en) | 2008-02-01 | 2013-09-19 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
| AP2011005537A0 (en) * | 2008-07-18 | 2011-02-28 | Novozymes Adenium Biotech As | Treatment of inflammatory diseases with mammal beta defensins. |
| SG172709A1 (en) | 2008-07-18 | 2011-07-28 | Novozymes Adenium Biotech As | Treatment of inflammatory bowel diseases with mammal beta defensins |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| US8828380B2 (en) * | 2009-09-10 | 2014-09-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for the treatment of pulmonary disease and method of producing proteins of use therein |
| US8410049B2 (en) | 2009-10-28 | 2013-04-02 | Cebix | Methods and kits for preventing hypoglycemia |
| KR101329774B1 (ko) | 2010-06-16 | 2013-11-15 | 주식회사 나이벡 | 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| US20130281361A1 (en) * | 2010-11-08 | 2013-10-24 | Pulmatrix, Inc. | Methods of treating and preventing rhinovirus infection |
| JP6219277B2 (ja) | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ | 炎症性腸疾患の経口治療 |
| US20130052213A1 (en) * | 2011-08-19 | 2013-02-28 | Novozymes A/S | Novel immunomodulatory peptide |
| US9464124B2 (en) * | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2653754C2 (ru) | 2012-12-06 | 2018-05-14 | Пин Фарма, Инк. | Лечение воспалительных, аутоиммунных и нейродегенеративных нарушений иммуннодепрессивными полипетидами, являющимися производными тат |
| MX2020004863A (es) | 2017-11-10 | 2020-10-14 | Defensin Therapeutics Aps | Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro. |
-
2017
- 2017-12-13 MX MX2019006848A patent/MX2019006848A/es unknown
- 2017-12-13 BR BR112019011844A patent/BR112019011844A2/pt not_active Application Discontinuation
- 2017-12-13 CN CN201780086292.7A patent/CN110290799A/zh active Pending
- 2017-12-13 RU RU2019120956A patent/RU2019120956A/ru unknown
- 2017-12-13 WO PCT/EP2017/082535 patent/WO2018108971A2/en not_active Ceased
- 2017-12-13 EP EP17835461.9A patent/EP3554532B1/en active Active
- 2017-12-13 CA CA3045079A patent/CA3045079A1/en active Pending
- 2017-12-13 US US16/468,051 patent/US11413328B2/en active Active
- 2017-12-13 JP JP2019531167A patent/JP2020512287A/ja not_active Ceased
- 2017-12-13 ES ES17835461T patent/ES2994381T3/es active Active
- 2017-12-13 AU AU2017376400A patent/AU2017376400A1/en active Pending
- 2017-12-13 KR KR1020197019175A patent/KR20190108106A/ko not_active Ceased
- 2017-12-13 SG SG10202012106WA patent/SG10202012106WA/en unknown
-
2022
- 2022-07-11 US US17/861,912 patent/US20230067261A1/en not_active Abandoned
-
2024
- 2024-10-22 JP JP2024186110A patent/JP2025013922A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017376400A1 (en) | 2019-06-20 |
| RU2019120956A (ru) | 2021-01-15 |
| WO2018108971A3 (en) | 2018-07-26 |
| KR20190108106A (ko) | 2019-09-23 |
| US20190336576A1 (en) | 2019-11-07 |
| CN110290799A (zh) | 2019-09-27 |
| EP3554532A2 (en) | 2019-10-23 |
| US20230067261A1 (en) | 2023-03-02 |
| JP2020512287A (ja) | 2020-04-23 |
| ES2994381T3 (en) | 2025-01-23 |
| EP3554532C0 (en) | 2024-09-25 |
| EP3554532B1 (en) | 2024-09-25 |
| SG10202012106WA (en) | 2021-01-28 |
| JP2025013922A (ja) | 2025-01-28 |
| CA3045079A1 (en) | 2018-06-21 |
| MX2019006848A (es) | 2019-10-07 |
| WO2018108971A2 (en) | 2018-06-21 |
| RU2019120956A3 (https=) | 2021-04-13 |
| US11413328B2 (en) | 2022-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019011844A2 (pt) | Uso de pelo menos uma defensina | |
| CY1123845T1 (el) | Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων | |
| MX377340B (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CY1119615T1 (el) | Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης | |
| WO2016033439A3 (en) | Compositions and methods for the treating an inflammatory disease or disorder | |
| BR112015015870A8 (pt) | composição farmacêutica, e, uso de uma composição farmacêutica | |
| BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
| CY1122098T1 (el) | Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3 | |
| BR112016029713A8 (pt) | uso de uma carboximetilcelulose reticulada e uso de um agente gelificante | |
| MX2020004054A (es) | Formulacion que comprende un profarmaco de gemcitabina. | |
| BR112012020693A8 (pt) | Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende | |
| TR201901110T4 (tr) | Empagliflozinin terapötik kullanımları. | |
| EP4335512A3 (en) | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| Prabhala et al. | Tristetraprolin and its role in regulation of airway inflammation | |
| MX2018005348A (es) | Composiciones y metodos para transduccion de tumores. | |
| WO2014169221A3 (en) | Cancer therapy | |
| BR112014030534A2 (pt) | composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| BR112016023450A2 (pt) | uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce | |
| BR112018001424A2 (pt) | compostos, composição farmacêutica e métodos para o tratamento de uma doença neoplásica, para o tratamento de um distúrbio inflamatório ou distúrbio autoimune, para o tratamento de uma doença neurodegenerativa e para o tratamento de um distúrbio metabólico | |
| WO2015051284A3 (en) | Small molecule securinine and norsecurinine analogs and their use in cancers inflammatory diseases and infections | |
| EP4410373A3 (en) | Nucleic acid simultaneously inhibiting expression of mtor gene and stat3 gene | |
| MX387286B (es) | Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora. | |
| CO2019011227A2 (es) | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |